Comparison
MOTS-c vs Semaglutide
Side-by-side of MOTS-c and Semaglutide. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
MOTS-c
MOTS-c peptide is a 16-amino-acid mitochondrial-derived peptide. Preclinical signals for insulin sensitivity, exercise capacity, dosage notes.
Semaglutide
Semaglutide for weight loss: GLP-1 agonist (Ozempic, Wegovy) drives 15-17% mean loss at 2.4 mg/week in STEP trials. Watch lean-mass loss.
Effects at a glance
MOTS-c
- •16-amino-acid peptide encoded in mitochondrial DNA (12S rRNA region); discovered 2015
- •Activates AMPK in skeletal muscle and liver; improves insulin sensitivity in rodent models
- •Circulating endogenous levels decline with age, motivating the longevity-restoration hypothesis
- •CohBar's MOTS-c analog CB4211 discontinued after phase 1b NASH readout did not meet endpoints
- •Anecdotal protocols use 5 to 10 mg subcutaneously 2 to 3 times weekly
- •Not on the WADA Prohibited List as of 2026; future scrutiny likely given exercise-mimetic mechanism
Semaglutide
- •Long-acting GLP-1 receptor agonist with a ~7-day half-life that supports once-weekly subcutaneous dosing
- •STEP trials reported ~15 to 17% mean body-weight loss at 2.4 mg/week over 68 weeks in adults with obesity
- •Lowers HbA1c by ~1.0 to 1.8 percentage points in type 2 diabetes versus placebo
- •SELECT trial showed reduced major cardiovascular events in adults with prior CVD and overweight or obesity
- •Up to 25 to 40% of weight lost can be lean mass; pairing with resistance training and protein intake mitigates this
- •GI effects (nausea, vomiting, constipation) drive most discontinuations and ease with slow titration
Side-by-side
| Attribute | MOTS-c | Semaglutide |
|---|---|---|
| Category | peptide | pharmaceutical |
| Also known as | Mitochondrial Open Reading Frame of the Twelve S rRNA-c, MOTSc | Ozempic, Wegovy, Rybelsus |
| Half-life (hr) ↗ | 0.5 | 168 |
| Typical dose (mg) ↗ | 5 | 2.4 |
| Dosing frequency | 2-3x weekly | weekly (SC); daily (oral Rybelsus) |
| Routes | subcutaneous | subcutaneous, oral |
| Onset (hr) | 1 | 24 |
| Peak (hr) | 4 | 72 |
| Molecular weight | 1880.18 | 4113.58 |
| Molecular formula | C82H132N22O25S2 | - |
| Mechanism | Mitochondrial-derived peptide that activates AMPK in skeletal muscle and liver, improves insulin sensitivity, and translocates to the nucleus under metabolic stress to modulate nuclear gene expression in retrograde mitochondrial signaling. | Long-acting GLP-1 receptor agonist; potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic satiety centers. |
| Legal status | Not FDA approved; research-use-only grey market; not currently on WADA Prohibited List | Prescription only (FDA-approved, EMA-approved) |
| WADA status | unknown | allowed |
| DEA / Rx | Not scheduled (research chemical) | Rx only (not a controlled substance); FDA-approved for type 2 diabetes (2017) and chronic weight management (2021) |
| Pregnancy | Insufficient data; not recommended | Not recommended; discontinue 2 months before planned pregnancy |
| CAS | 1627580-64-6 | 910463-68-2 |
| PubChem CID | 139599184 | 56843331 |
| Wikidata | Q24832108 | Q27089394 |
Safety profile
MOTS-c
Common side effects
- injection-site irritation
- transient fatigue
- headache (anecdotal)
Contraindications
- pregnancy
- lactation
- active malignancy (theoretical)
- severe hypoglycemia risk on concurrent insulin or sulfonylurea
Interactions
- insulin: additive insulin sensitization may increase hypoglycemia risk(moderate)
- metformin: both activate AMPK; theoretical additive metabolic effect, no controlled data(minor)
- sulfonylureas: increased hypoglycemia risk via additive insulin sensitization(moderate)
Semaglutide
Common side effects
- nausea
- vomiting
- diarrhea
- constipation
- decreased appetite
- injection-site reactions
- fatigue
Contraindications
- personal or family history of medullary thyroid carcinoma
- multiple endocrine neoplasia type 2
- pregnancy
- history of pancreatitis (use caution)
Interactions
- insulin: additive hypoglycemia risk; insulin dose typically reduced(major)
- sulfonylureas (glipizide, glyburide): hypoglycemia risk, sulfonylurea dose often reduced(major)
- oral medications (general): delayed gastric emptying can alter absorption kinetics(moderate)
- warfarin: monitor INR due to altered absorption(moderate)
Which Should You Take?
Semaglutide comes out ahead for most readers on the criteria we weight: 2 catalogued goals, prescription-only, oral dosing, with a Tier-A outcome catalogued. MOTS-c is the right call when one of the conditionals below applies.
- → If your priority is healthspan extension, pick MOTS-c.
- → If your priority is mitochondrial function, pick MOTS-c.
- → If your priority is fat loss, pick Semaglutide.
Edge case: If you cannot self-administer injections, Semaglutide is the only oral option in this pair.
Default choice: Semaglutide. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for MOTS-c only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between MOTS-c and Semaglutide?
MOTS-c and Semaglutide differ in category (peptide vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, MOTS-c or Semaglutide?
MOTS-c half-life is 0.5 hours; Semaglutide half-life is 168 hours.
Can you stack MOTS-c with Semaglutide?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper